{
      "Rank": 119,
      "Acronym": [
            "START"
      ],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [
            "No"
      ],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [
            "No"
      ],
      "ArmGroupDescription": [
            "A dose-escalation with 3 cohorts with 3 subjects/cohort who receive doses of 1, 5 and 10 million cells/kg predicted body weight (PBW). Proceed from lower dose to next higher dose if no safety concerns for each cohort."
      ],
      "ArmGroupInterventionName": [
            "Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells"
      ],
      "ArmGroupLabel": [
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells"
      ],
      "ArmGroupType": [
            "Experimental"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [
            "<=18 years",
            "Between 18 and 65 years",
            ">=65 years",
            "Female",
            "Male",
            "Hispanic or Latino",
            "Not Hispanic or Latino",
            "Unknown or Not Reported",
            "American Indian or Alaska Native",
            "Asian",
            "Native Hawaiian or Other Pacific Islander",
            "Black or African American",
            "White",
            "More than one race",
            "Unknown or Not Reported"
      ],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT01775774"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [
            "United States",
            "Pneumonia",
            "Aspiration",
            "Sepsis",
            "Pre-eclampsia"
      ],
      "BaselineDenomCountGroupId": [
            "BG000",
            "BG001",
            "BG002",
            "BG003"
      ],
      "BaselineDenomCountValue": [
            "3",
            "3",
            "3",
            "9"
      ],
      "BaselineDenomUnits": [
            "Participants"
      ],
      "BaselineGroupDescription": [
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
            "Total of all reporting groups"
      ],
      "BaselineGroupId": [
            "BG000",
            "BG001",
            "BG002",
            "BG003"
      ],
      "BaselineGroupTitle": [
            "Human Mesenchymal Stem Cells 1 Million Cells/kg PBW",
            "Mesenchymal Stem Cells 5 Million Cells/kg PBW",
            "Mesenchymal Stem Cells 10 Million Cells/kg PBW",
            "Total"
      ],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [
            "Acute Physiology and Chronic Health Evaluation III score, a severity-of-disease classification system. Higher score predicts worse clinical outcome. The scale of APACHE III is 0 - 299, where 0 = best outcome and 299 = worst outcome."
      ],
      "BaselineMeasureDispersionType": [
            "Full Range",
            "Full Range"
      ],
      "BaselineMeasureParamType": [
            "Count of Participants",
            "Mean",
            "Count of Participants",
            "Count of Participants",
            "Count of Participants",
            "Number",
            "Mean",
            "Number"
      ],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [
            "Age, Categorical",
            "Age, Continuous",
            "Sex: Female, Male",
            "Ethnicity (NIH/OMB)",
            "Race (NIH/OMB)",
            "Region of Enrollment",
            "APACHE III Score",
            "Primary cause of ARDS"
      ],
      "BaselineMeasureUnitOfMeasure": [
            "Participants",
            "years",
            "Participants",
            "Participants",
            "Participants",
            "participants",
            "scores on a scale",
            "participants"
      ],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG000",
            "BG001",
            "BG002",
            "BG003"
      ],
      "BaselineMeasurementLowerLimit": [
            "29",
            "46",
            "38",
            "29",
            "62",
            "64",
            "54",
            "54"
      ],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [
            "86",
            "67",
            "55",
            "86",
            "111",
            "115",
            "108",
            "115"
      ],
      "BaselineMeasurementValue": [
            "0",
            "0",
            "0",
            "0",
            "2",
            "2",
            "3",
            "7",
            "1",
            "1",
            "0",
            "2",
            "58.0",
            "58.3",
            "48.3",
            "54.9",
            "3",
            "3",
            "1",
            "7",
            "0",
            "0",
            "2",
            "2",
            "0",
            "2",
            "0",
            "2",
            "3",
            "1",
            "3",
            "7",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "1",
            "0",
            "0",
            "1",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "2",
            "3",
            "2",
            "7",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "1",
            "1",
            "3",
            "3",
            "3",
            "9",
            "91.7",
            "89.7",
            "88.3",
            "89.9",
            "1",
            "1",
            "2",
            "4",
            "1",
            "2",
            "0",
            "3",
            "0",
            "0",
            "1",
            "1",
            "1",
            "0",
            "0",
            "1"
      ],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "This is a Phase 1, open label, dose escalation, multi-center clinical trial of Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells (hMSCs) for the treatment of Acute Respiratory Distress Syndrome (ARDS). The purpose of this study is to assess the safety of hMSCs in patients with ARDS."
      ],
      "BriefTitle": [
            "Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [
            "NIH",
            "OTHER",
            "OTHER",
            "OTHER",
            "OTHER"
      ],
      "CollaboratorName": [
            "National Heart, Lung, and Blood Institute (NHLBI)",
            "Massachusetts General Hospital",
            "Stanford University",
            "University of Pittsburgh",
            "University of Minnesota"
      ],
      "CompletionDate": [
            "February 2015"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "Acute Respiratory Distress Syndrome"
      ],
      "ConditionAncestorId": [
            "D000004194",
            "D000010335",
            "D000008171",
            "D000012140",
            "D000012120",
            "D000007235",
            "D000007232",
            "D000055370"
      ],
      "ConditionAncestorTerm": [
            "Disease",
            "Pathologic Processes",
            "Lung Diseases",
            "Respiratory Tract Diseases",
            "Respiration Disorders",
            "Infant, Premature, Diseases",
            "Infant, Newborn, Diseases",
            "Lung Injury"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC23",
            "All",
            "BC08",
            "BC16",
            "BC26",
            "BXS",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Symptoms and General Pathology",
            "All Conditions",
            "Respiratory Tract (Lung and Bronchial) Diseases",
            "Diseases and Abnormalities at or Before Birth",
            "Wounds and Injuries",
            "Urinary Tract, Sexual Organs, and Pregnancy Conditions",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Syndrome",
            "Respiratory Distress Syndrome",
            "Respiratory Distress Syndrome",
            "Acute Respiratory Distress Syndrome",
            "Respiratory Distress Syndrome",
            "Acute Respiratory Distress Syndrome"
      ],
      "ConditionBrowseLeafId": [
            "M15507",
            "M14117",
            "M14116",
            "M27297",
            "M27296",
            "M10320",
            "M14129",
            "M14109",
            "M25022",
            "M9431",
            "M9428",
            "T4927",
            "T192",
            "T170"
      ],
      "ConditionBrowseLeafName": [
            "Syndrome",
            "Respiratory Distress Syndrome",
            "Respiratory Distress Syndrome, Newborn",
            "Acute Lung Injury",
            "Lung Injury",
            "Lung Diseases",
            "Respiratory Tract Diseases",
            "Respiration Disorders",
            "Premature Birth",
            "Infant, Premature, Diseases",
            "Infant, Newborn, Diseases",
            "Respiratory Distress Syndrome, Infant",
            "Acute Respiratory Distress Syndrome",
            "Acute Graft Versus Host Disease"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "high",
            "high",
            "low"
      ],
      "ConditionMeshId": [
            "D000012128",
            "D000012127",
            "D000055371",
            "D000013577"
      ],
      "ConditionMeshTerm": [
            "Respiratory Distress Syndrome",
            "Respiratory Distress Syndrome, Newborn",
            "Acute Lung Injury",
            "Syndrome"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "N/A"
      ],
      "DesignInterventionModel": [
            "Single Group Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [
            "The primary objective of this study is to assess the safety of intravenous infusion of Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells (hMSCs) in patients with ARDS."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nPatients will be eligible for inclusion if they meet all of the below criteria. Criteria 1-3 must all be present within a 24-hour time period and at the time of enrollment:\n\nAcute onset (defined below) of:\n\nA need for positive pressure ventilation by an endotracheal or tracheal tube with a PaO2/FiO2 ratio < 200 with at least 8 cm H2O positive end-expiratory airway pressure (PEEP)\nBilateral infiltrates consistent with pulmonary edema on frontal chest radiograph\nNo clinical evidence of left atrial hypertension for bilateral pulmonary infiltrates.\n\nIn addition to meeting inclusion criteria, enrollment must occur within 96-hours of first meeting ARDS criteria per the Berlin definition of ARDS.\n\nExclusion Criteria:\n\nAge less than 18 years\nGreater than 96 hours since first meeting ARDS criteria per the Berlin definition of ARDS\nPregnant or breast-feeding\nPrisoner\nPresence of any active malignancy (other than non-melanoma skin cancer) that required treatment within the last 2 years\nAny other irreversible disease or condition for which 6-month mortality is estimated to be greater than 50%\nModerate to severe liver failure (Childs-Pugh Score > 12)\nSevere chronic respiratory disease with a PaCO2 > 50 mm Hg or the use of home oxygen\nPatient, surrogate, or physician not committed to full support (exception: a patient will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest).\nMajor trauma in the prior 5 days\nLung transplant patient\nNo consent/inability to obtain consent\nMoribund patient not expected to survive 24 hours\nWHO Class III or IV pulmonary hypertension\nDocumented deep venous thrombosis or pulmonary embolism within past 3 months\nNo arterial line/no intent to place an arterial line\nNo intent/unwillingness to follow lung protective ventilation strategy or fluid management protocol\nCurrently receiving extracorporeal life support (ECLS) or high-frequency oscillatory ventilation (HFOV)"
      ],
      "EnrollmentCount": [
            "9"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously.",
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously.",
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously."
      ],
      "EventGroupId": [
            "EG000",
            "EG001",
            "EG002"
      ],
      "EventGroupOtherNumAffected": [
            "0",
            "1",
            "1"
      ],
      "EventGroupOtherNumAtRisk": [
            "3",
            "3",
            "3"
      ],
      "EventGroupSeriousNumAffected": [
            "2",
            "1",
            "0"
      ],
      "EventGroupSeriousNumAtRisk": [
            "3",
            "3",
            "3"
      ],
      "EventGroupTitle": [
            "Human Mesenchymal Stem Cells: 1 Million Cells/kg PBW",
            "Human Mesenchymal Stem Cells: 5 Million Cells/kg PBW",
            "Human Mesenchymal Stem Cells: 10 Million Cells/kg PBW"
      ],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [
            "0"
      ],
      "EventsTimeFrame": [
            "1 year"
      ],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [
            "FG000",
            "FG001",
            "FG002",
            "FG000",
            "FG001",
            "FG002",
            "FG000",
            "FG001",
            "FG002"
      ],
      "FlowAchievementNumSubjects": [
            "3",
            "3",
            "3",
            "3",
            "3",
            "3",
            "0",
            "0",
            "0"
      ],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts."
      ],
      "FlowGroupId": [
            "FG000",
            "FG001",
            "FG002"
      ],
      "FlowGroupTitle": [
            "Human Mesenchymal Stem Cells 1 Million Cells/kg PBW",
            "Human Mesenchymal Stem Cells 5 Million Cells/kg PBW",
            "Human Mesenchymal Stem Cells 10 Million Cells/kg PBW"
      ],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [
            "STARTED",
            "COMPLETED",
            "NOT COMPLETED"
      ],
      "FlowPeriodTitle": [
            "Overall Study"
      ],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [
            "This dose-escalation Phase 1 clinical trial with 3 cohorts with 3 subjects/cohort was performed in 7 centers in USA between July 2013 to January 2014."
      ],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells"
      ],
      "InterventionBrowseBranchAbbrev": [],
      "InterventionBrowseBranchName": [],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [],
      "InterventionBrowseLeafName": [],
      "InterventionBrowseLeafRelevance": [],
      "InterventionDescription": [
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously."
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Biological"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Acute Respiratory Distress Syndrome",
            "Acute Lung Injury",
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "August 14, 2017"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "May 2, 2017"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Michael A. Matthay"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "San Francisco",
            "Stanford",
            "Boston",
            "Pittsburgh"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "United States",
            "United States",
            "United States",
            "United States"
      ],
      "LocationFacility": [
            "University of California San Francisco Medical Center",
            "Stanford University Medical Center",
            "Massachusetts General Hospital",
            "University of Pittsburgh Medical Center"
      ],
      "LocationState": [
            "California",
            "California",
            "Massachusetts",
            "Pennsylvania"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "94143",
            "94305",
            "02114",
            "15213"
      ],
      "MaximumAge": [],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "A Phase 1 Multi-center Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stem Cells for the Treatment of Acute Respiratory Distress Syndrome"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "University of California, San Francisco"
      ],
      "OrgStudyId": [
            "ARDS MSC 001"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [
            "Non-systematic Assessment",
            "Non-systematic Assessment"
      ],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [
            "Hepatobiliary disorders",
            "Respiratory, thoracic and mediastinal disorders"
      ],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [
            "EG000",
            "EG001",
            "EG002",
            "EG000",
            "EG001",
            "EG002"
      ],
      "OtherEventStatsNumAffected": [
            "0",
            "1",
            "0",
            "0",
            "0",
            "1"
      ],
      "OtherEventStatsNumAtRisk": [
            "3",
            "3",
            "3",
            "3",
            "3",
            "3"
      ],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [
            "Elevated liver function tests",
            "Pulmonary embolism"
      ],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [
            "OG000",
            "OG001",
            "OG002",
            "OG000",
            "OG001",
            "OG002",
            "OG000",
            "OG001",
            "OG002",
            "OG000",
            "OG001",
            "OG002",
            "OG000",
            "OG001",
            "OG002",
            "OG000",
            "OG001",
            "OG002",
            "OG000",
            "OG001",
            "OG002"
      ],
      "OutcomeDenomCountValue": [
            "3",
            "3",
            "3",
            "3",
            "3",
            "3",
            "3",
            "3",
            "3",
            "3",
            "3",
            "3",
            "3",
            "3",
            "3",
            "3",
            "3",
            "3",
            "3",
            "3",
            "3"
      ],
      "OutcomeDenomUnits": [
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants"
      ],
      "OutcomeGroupDescription": [
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts.",
            "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells were administered intravenously into the 3 planned dosing cohorts."
      ],
      "OutcomeGroupId": [
            "OG000",
            "OG001",
            "OG002",
            "OG000",
            "OG001",
            "OG002",
            "OG000",
            "OG001",
            "OG002",
            "OG000",
            "OG001",
            "OG002",
            "OG000",
            "OG001",
            "OG002",
            "OG000",
            "OG001",
            "OG002",
            "OG000",
            "OG001",
            "OG002"
      ],
      "OutcomeGroupTitle": [
            "Human Mesenchymal Stem Cells: 1 Million Cellls/kg PBW",
            "Human Mesenchymal Stem Cells: 5 Million Cellls/kg PBW",
            "Human Mesenchymal Stem Cells: 10 Million Cellls/kg PBW",
            "Human Mesenchymal Stem Cells: 1 Million Cellls/kg PBW",
            "Human Mesenchymal Stem Cells: 5 Million Cellls/kg PBW",
            "Human Mesenchymal Stem Cells: 10 Million Cellls/kg PBW",
            "Human Mesenchymal Stem Cells: 1 Million Cellls/kg PBW",
            "Human Mesenchymal Stem Cells: 5 Million Cellls/kg PBW",
            "Human Mesenchymal Stem Cells: 10 Million Cellls/kg PBW",
            "Human Mesenchymal Stem Cells: 1 Million Cellls/kg PBW",
            "Human Mesenchymal Stem Cells: 5 Million Cellls/kg PBW",
            "Human Mesenchymal Stem Cells: 10 Million Cellls/kg PBW",
            "Human Mesenchymal Stem Cells: 1 Million Cellls/kg PBW",
            "Human Mesenchymal Stem Cells: 5 Million Cellls/kg PBW",
            "Human Mesenchymal Stem Cells: 10 Million Cellls/kg PBW",
            "Human Mesenchymal Stem Cells: 1 Million Cellls/kg PBW",
            "Human Mesenchymal Stem Cells: 5 Million Cellls/kg PBW",
            "Human Mesenchymal Stem Cells: 10 Million Cellls/kg PBW",
            "Human Mesenchymal Stem Cells: 1 Million Cellls/kg PBW",
            "Human Mesenchymal Stem Cells: 5 Million Cellls/kg PBW",
            "Human Mesenchymal Stem Cells: 10 Million Cellls/kg PBW"
      ],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [
            "Any of the following occurring within 6 h of mesenchymal stem-cell infusion:\n\nAddition of a third vasopressor or an increase in vasopressor dose greater than or equal to the following:\nNorepinephrine: 10 \u03bcg per min\nPhenylephrine: 100 \u03bcg per min\nDopamine: 10 \u03bcg/kg per min\nEpinephrine: 0\u00b71 \u03bcg/kg per min\nHypoxaemia requiring an increase in the fraction of inspired oxygen of \u22650\u00b72 and increase in positive end-expiratory airway pressure level of 5 cm H2O or more to maintain transcutaneous oxygen saturations in the target range of 88-95%\nNew cardiac arrhythmia requiring cardioversion\nNew ventricular tachycardia, ventricular fi brillation, or asystole\nA clinical scenario consistent with transfusion incompatibility or transfusion-related infection\nCardiac arrest or death within 24 h of mesenchymal stem-cell infusion",
            "The number of participants with a severe adverse event during the study was assessed.",
            "Ventilator Free Days (VFDs) to day 28 were defined as the number of days from the time of initiating unassisted breathing to day 28 after randomization, assuming survival for at least two consecutive calendar days after initiating unassisted breathing and continued unassisted breathing to day 28. If a subject received assisted breathing at day 27 or died prior to day 28, a value of zero VFDs was given.",
            "Days on vasopressor to day 28 after study enrollment",
            "The number of subjects alive at study day 60. Those subjects discharged home prior to day 60 were counted as alive at day 60.",
            "The number of patients expired at hospital discharge."
      ],
      "OutcomeMeasureDispersionType": [
            "Full Range",
            "Full Range",
            "Full Range"
      ],
      "OutcomeMeasureParamType": [
            "Number",
            "Number",
            "Median",
            "Median",
            "Median",
            "Number",
            "Number"
      ],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted"
      ],
      "OutcomeMeasureTimeFrame": [
            "24 hours",
            "Investigators conducted daily assessments for the presence of adverse events (AE) from enrollment through study day 28 or hospital discharge, whichever occurred first.",
            "time of initiating unassisted breathing to day 28",
            "28 days",
            "28 days after study enrollment",
            "60 days after randomization",
            "From study enrollment to Hospital discharge"
      ],
      "OutcomeMeasureTitle": [
            "Incidence of Pre-specified Infusion Associated Adverse Events",
            "Incidence of Severe Adverse Events (SAEs)",
            "Ventilator Free Days at Study Day 28",
            "Duration of Vasopressor Use (Days)",
            "ICU Free Days to Day 28",
            "Hospital Survival to Day 60",
            "Mortality at Hospital Discharge"
      ],
      "OutcomeMeasureType": [
            "Primary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary"
      ],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [
            "participants",
            "participants",
            "day",
            "day",
            "day",
            "participants",
            "participants"
      ],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [
            "OG000",
            "OG001",
            "OG002",
            "OG000",
            "OG001",
            "OG002",
            "OG000",
            "OG001",
            "OG002",
            "OG000",
            "OG001",
            "OG002",
            "OG000",
            "OG001",
            "OG002",
            "OG000",
            "OG001",
            "OG002",
            "OG000",
            "OG001",
            "OG002"
      ],
      "OutcomeMeasurementLowerLimit": [
            "0",
            "0",
            "12",
            "0",
            "0",
            "0",
            "0",
            "0",
            "9"
      ],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [
            "24",
            "27",
            "26",
            "10",
            "3",
            "0",
            "24",
            "26",
            "22"
      ],
      "OutcomeMeasurementValue": [
            "0",
            "0",
            "0",
            "2",
            "1",
            "0",
            "18",
            "22",
            "20",
            "4",
            "2",
            "0",
            "14",
            "21",
            "18",
            "2",
            "2",
            "3",
            "1",
            "1",
            "0"
      ],
      "OverallOfficialAffiliation": [],
      "OverallOfficialName": [],
      "OverallOfficialRole": [],
      "OverallStatus": [
            "Completed"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1"
      ],
      "PointOfContactEMail": [
            "michael.matthay@ucsf.edu"
      ],
      "PointOfContactOrganization": [
            "University of California San Francisco"
      ],
      "PointOfContactPhone": [
            "415-353-1206"
      ],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [
            "Michael A. Matthay, MD"
      ],
      "PrimaryCompletionDate": [
            "February 2014"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [
            "Any of the following occurring within 6 h of mesenchymal stem-cell infusion:\n\nAddition of a third vasopressor or an increase in vasopressor dose greater than or equal to the following:\nNorepinephrine: 10 \u03bcg per min\nPhenylephrine: 100 \u03bcg per min\nDopamine: 10 \u03bcg/kg per min\nEpinephrine: 0\u00b71 \u03bcg/kg per min\nHypoxaemia requiring an increase in the fraction of inspired oxygen of \u22650\u00b72 and increase in positive end-expiratory airway pressure level of 5 cm H2O or more to maintain transcutaneous oxygen saturations in the target range of 88-95%\nNew cardiac arrhythmia requiring cardioversion\nNew ventricular tachycardia, ventricular fi brillation, or asystole\nA clinical scenario consistent with transfusion incompatibility or transfusion-related infection\nCardiac arrest or death within 24 h of mesenchymal stem-cell infusion"
      ],
      "PrimaryOutcomeMeasure": [
            "Incidence of Pre-specified Infusion Associated Adverse Events"
      ],
      "PrimaryOutcomeTimeFrame": [
            "24 hours"
      ],
      "ReferenceCitation": [
            "Wilson JG, Liu KD, Zhuo H, Caballero L, McMillan M, Fang X, Cosgrove K, Vojnik R, Calfee CS, Lee JW, Rogers AJ, Levitt J, Wiener-Kronish J, Bajwa EK, Leavitt A, McKenna D, Thompson BT, Matthay MA. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med. 2015 Jan;3(1):24-32. doi: 10.1016/S2213-2600(14)70291-7. Epub 2014 Dec 17.",
            "Liu KD, Wilson JG, Zhuo H, Caballero L, McMillan ML, Fang X, Cosgrove K, Calfee CS, Lee JW, Kangelaris KN, Gotts JE, Rogers AJ, Levitt JE, Wiener-Kronish JP, Delucchi KL, Leavitt AD, McKenna DH, Thompson BT, Matthay MA. Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome. Ann Intensive Care. 2014 Jul 3;4:22. doi: 10.1186/s13613-014-0022-z. eCollection 2014.",
            "Asmussen S, Ito H, Traber DL, Lee JW, Cox RA, Hawkins HK, McAuley DF, McKenna DH, Traber LD, Zhuo H, Wilson J, Herndon DN, Prough DS, Liu KD, Matthay MA, Enkhbaatar P. Human mesenchymal stem cells reduce the severity of acute lung injury in a sheep model of bacterial pneumonia. Thorax. 2014 Sep;69(9):819-25. doi: 10.1136/thoraxjnl-2013-204980. Epub 2014 Jun 2."
      ],
      "ReferencePMID": [
            "25529339",
            "25593740",
            "24891325"
      ],
      "ReferenceType": [
            "result",
            "derived",
            "derived"
      ],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [
            "University of California, San Francisco"
      ],
      "ResponsiblePartyInvestigatorFullName": [
            "Michael A. Matthay"
      ],
      "ResponsiblePartyInvestigatorTitle": [
            "Prinicpal Investigator"
      ],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor-Investigator"
      ],
      "ResultsFirstPostDate": [
            "August 14, 2017"
      ],
      "ResultsFirstPostDateType": [
            "Actual"
      ],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [
            "December 18, 2015"
      ],
      "ResultsFirstSubmitQCDate": [
            "May 2, 2017"
      ],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [
            "1U01HL108713-01"
      ],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [
            "https://reporter.nih.gov/quickSearch/1U01HL108713-01"
      ],
      "SecondaryIdType": [
            "U.S. NIH Grant/Contract"
      ],
      "SecondaryOutcomeDescription": [
            "The number of participants with a severe adverse event during the study was assessed.",
            "Ventilator Free Days (VFDs) to day 28 were defined as the number of days from the time of initiating unassisted breathing to day 28 after randomization, assuming survival for at least two consecutive calendar days after initiating unassisted breathing and continued unassisted breathing to day 28. If a subject received assisted breathing at day 27 or died prior to day 28, a value of zero VFDs was given.",
            "Days on vasopressor to day 28 after study enrollment",
            "The number of subjects alive at study day 60. Those subjects discharged home prior to day 60 were counted as alive at day 60.",
            "The number of patients expired at hospital discharge."
      ],
      "SecondaryOutcomeMeasure": [
            "Incidence of Severe Adverse Events (SAEs)",
            "Ventilator Free Days at Study Day 28",
            "Duration of Vasopressor Use (Days)",
            "ICU Free Days to Day 28",
            "Hospital Survival to Day 60",
            "Mortality at Hospital Discharge"
      ],
      "SecondaryOutcomeTimeFrame": [
            "Investigators conducted daily assessments for the presence of adverse events (AE) from enrollment through study day 28 or hospital discharge, whichever occurred first.",
            "time of initiating unassisted breathing to day 28",
            "28 days",
            "28 days after study enrollment",
            "60 days after randomization",
            "From study enrollment to Hospital discharge"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [
            "Non-systematic Assessment",
            "Non-systematic Assessment"
      ],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [
            "Respiratory, thoracic and mediastinal disorders",
            "Vascular disorders"
      ],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [
            "EG000",
            "EG001",
            "EG002",
            "EG000",
            "EG001",
            "EG002"
      ],
      "SeriousEventStatsNumAffected": [
            "1",
            "1",
            "0",
            "1",
            "0",
            "0"
      ],
      "SeriousEventStatsNumAtRisk": [
            "3",
            "3",
            "3",
            "3",
            "3",
            "3"
      ],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [
            "Multiorgan failure",
            "Infarcts of kidneys, spleen and brain"
      ],
      "StartDate": [
            "July 2013"
      ],
      "StartDateType": [],
      "StatusVerifiedDate": [
            "May 2017"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "January 25, 2013"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "January 18, 2013"
      ],
      "StudyFirstSubmitQCDate": [
            "January 24, 2013"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}